Currently, the second-and third-generation enzyme immu-infection, assessment of the severity of liver disease, monitornoassays (EIA-2 and EIA-3) for hepatitis C virus antibody ing progress of liver disease, determination of the likelihood (anti-HCV) are the most practical screening tests for the diag-of response to interferon therapy, and monitoring of response nosis of HCV infection. The need for and the choice of supple-to treatment. mentary or confirmatory tests depend on the clinical setting and the likelihood of a true-positive EIA result. Detection of DIAGNOSIS OF HEPATITIS C HCV RNA in serum by polymerase chain reaction (PCR) assay Anti-HCV Tests. Currently, the second-generation enzyme is the gold standard for the diagnosis of HCV infection. Howimmunoassays (EIA-2) for anti-HCV are the most practical ever, the lack of uniformity in current PCR assays has tarscreening tests for the diagnosis of HCV infection in the nished this standard. Confirmatory tests for the diagnosis of United States. 1,2 These assays detect antibodies to recombi-HCV infection are in general unnecessary in anti-HCV-posinant HCV antigens from the core (C22) and nonstructural tive patients who present with chronic liver disease. When regions 3 (C33) and 4 (C-100). They are easy to perform indicated, the most appropriate test in this setting is a qualitaand the results are highly reproducible. Recently, third-gentive PCR assay for HCV RNA. Confirmatory tests should aleration EIAs (EIA-3) have been approved by the Food and ways be performed in anti-HCV-positive blood donors and Drug Administration for blood donor screening. EIA-3 differs individuals with normal aminotransferase levels. The most from EIA-2 in that it incorporates additional recombinant appropriate approach is to retest for anti-HCV using recombi-HCV antigen from the nonstructural region 5 (NS5). EIA-3 is nant immunoblot assay (RIBA) and then test for HCV RNA slightly more sensitive than EIA-2, but most of the improved using PCR assay in those who are RIBA positive or indetermisensitivity appears to be attributable to increased detection nate. Liver histology is the gold standard in assessing severity of anti-C33 and not the addition of NS5. [3][4][5] The secondof liver disease. Quantitative tests for serum HCV RNA levels generation recombinant immunoblot assays (RIBA-2) permit do not help to determine the severity of liver disease. At the the detection of antibodies to individual recombinant HCV moment, HCV genotyping should be considered a research antigens: C22, C33, C-100, and 5-1-1 (overlaps with C-100). tool and not a part of the diagnostic work-up in clinical pracPatients who react to two or more HCV antigens are considtice. The goals of treatment for chronic hepatitis C are susered to be RIBA positive, whereas those who react to one tained biochemical and virological response. Viral clearance HCV antigen only are considered to have indeterminate reshould be determined by qualitative PCR assay. Quantifying sults. 1,2 RIBAs are technically more demanding than EIAs, serum HCV RNA level can help in predicting response to but they are simpler, more standardized, and more reproducinterferon treatment, but further studies using more standardible than tests for HCV RNA. RIBAs confer increased specificized assays are needed to determine if these values can be ity compared with EIAs. Nevertheless, RIBA positivity is not used to select patients for treatment. (HEPATOLOGY 1997; 26 always indicative of ongoing HCV infection because patients (Suppl 1):48S-56S.) with recovered HCV infection may remain anti-HCV positive for many years. RIBA-3, which differs from RIBA-2 in having Diagnosis of hepatitis C involves confirmation of the pres-additional recombinant proteins from NS5 and synthetic pepence of hepatitis C virus (HCV) infection and assessment of tides from the core and NS3 antigens, has helped to resolve the severity of liver disease. In addition, the diagnostic work-many of the RIBA-2 indeterminate samples, but only approxiup should include investigations that may help to predict mately 50% of the RIBA-3-positive blood donors are HCV prognosis and response to treatment. This review focuses on RNA positive by polymerase chain reaction (PCR) assays. Eq/mL, whereas that of the second-generation bDNA assay is MI 48109. Fax: (313) 936-7392. 200,000 Eq/mL. 8,9 Thus, 10% to 30% of patients with chronic
have undetectable HCV RNA if tested by the bDNA assay. 8, [10] [11] [12] [13] [14] Although the detection of HCV RNA by PCR assays is considered to be the gold standard for the diagnosis of HCV infection, the lack of uniformity in current PCR assays has tarnished this standard. In a recent international collaborative study, 86 laboratories submitted 136 data forms on a panel of coded sera. 15 Of these data sets, 99 were tested using a PCR assay developed in-house, 28 using a commercially available PCR assay (AMPLICOR; Roche Molecular Diagnostics Systems, Branchburg, NJ), and 9 using other amplification methods. Only 16% of the data forms had faultless results, 29% missed the weak positive sample only, and 55% had false-positive and/or false-negative results. These data portant for quantitative HCV RNA assays where up to 1,000-Pos, positive; ind, indeterminate; neg, negative; FU, follow-up.
fold differences in HCV RNA levels have been reported.
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HCV Genotyping. There are at least six genotypes of HCV and more than 30 subtypes. HCV genotyping provides im-cally indicated. Studies performed on recently collected sera portant information in epidemiological studies but does not in experienced laboratories have yielded HCV RNA detection help in confirming the diagnosis of HCV infection.
rates of greater than 90%. 20 Thus, it can be argued that supLiver Biopsy. Characteristic histological features that are plementary and confirmatory tests for the diagnosis of HCV more frequently found in patients with chronic hepatitis C infection are in general unnecessary in anti-HCV (EIA-2)-than in patients with chronic hepatitis B or autoimmune positive patients who present with chronic liver disease, espehepatitis have been reported. [16] [17] [18] However, none of these cially those who have risk factors for HCV infection. When features is pathognomonic for chronic hepatitis C. Liver bi-confirmatory tests are performed, PCR assays for HCV RNA opsies are not necessary for the diagnosis of HCV infection. are more appropriate than RIBA. Although qualitative PCR DIAGNOSTIC ALGORITHMS assay for HCV RNA will suffice to confirm the diagnosis, quantitative tests may be considered if treatment is contemThe need for and the choice of supplementary and confirplated (vide infra) because many studies have found that matory tests depend on the clinical setting and the likelihood pretreatment serum HCV RNA level is the most important of a true-positive EIA result.
9,19 Different diagnostic algoindependent predictor of response to treatment. rithms may be considered for patients presenting with Anti-HCV-Positive (EIA-2) Blood Donors and Individuals With chronic liver disease or elevated alanine aminotransferase Normal ALT Levels. Contrary to patients with chronic liver (ALT) levels as opposed to asymptomatic blood donors or disease, only 30% to 40% anti-HCV (EIA-2)-positive blood individuals with normal ALT levels. It can also be argued donors are RIBA positive and 20% to 40% are RIBA indeterthat individuals with or without risk factors for HCV infecminate (Fig. 2) . The percentage of EIA-2-positive blood dotion should be evaluated differently. However, identification nors who have detectable HCV RNA in serum when tested of risk factors is more subjective and dependent on the expeby PCR assay varies from 70% to 90% for those who are rience and skills of the clinician. In view of the possibility RIBA positive to 2% to 40% for those who are RIBA indeterof a false-negative EIA-2 result, modified diagnostic algominate, to none among those who are RIBA negative, giving rithms are recommended for immunocompromised patients an overall detection rate of 35% to 45% (Table 1) . [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Thus, and patients with acute hepatitis C.
supplementary or confirmatory tests for HCV infection
Anti-HCV-Positive (EIA-2) Patients Presenting With Chronic
should always be performed in EIA-2-positive blood donors. Liver Disease or Elevated ALT Level. The majority (78%-98%) Two algorithms can be considered for the evaluation of EIAof patients who present with chronic liver disease and are 2-positive blood donors (Fig. 2) . anti-HCV positive by EIA-2 have chronic HCV infection as
The first algorithm is to retest for anti-HCV using RIBA, defined by the detection of HCV RNA in serum using PCR and then test for HCV RNA using PCR assay in those who assays (Fig. 1) .
10,20-23 Most (80%-90%) EIA-2-positive paare RIBA positive or indeterminate. RIBA-negative donors tients with chronic liver disease are RIBA positive, 90% of can be dismissed. PCR-positive donors should be further whom will be HCV RNA positive; approximately 10% are evaluated to assess the severity of liver disease. The disposi-RIBA indeterminate, 60% to 70% of whom will be HCV RNA tion of RIBA-positive or -indeterminate donors who are PCR positive. 22, 23 Failure to detect HCV RNA in all patients may negative is less clear. Several studies have found that individbe related to insensitivity of the PCR assays, degradation of uals with isolated reactivity to C-100 or 5-1-1 are invariably HCV RNA during sample collection and storage, intermittent PCR negative. 27, 28, 33 However, HCV RNA can be detected in viremia, resolved HCV infection, or false-positive EIA result.
0% to 80% of individuals with isolated reactivity to C22 or These patients should be retested for HCV RNA using the C33. 27, 29, 34 Histological evidence of chronic hepatitis has been most reliable PCR assay available, and attention should be reported in 7.5% to 18% of RIBA-indeterminate donors, 29, 35 paid to optimize the conditions for sample collection and but liver disease appeared to be confined to those who were storage to prevent RNA degradation. Investigations into other PCR positive. Among RIBA-positive donors, three studies causes of chronic liver disease should be performed in patients who are repeatedly HCV RNA negative and when clini-reported that 6 of 29 (21%) PCR-negative donors had chronic AID Hepa 0007 / 5p25$$$122 08-01-97 08:22:12 hepas WBS: Hepatology step approach. However, it is not clear if all the PCR-negative donors can be safely dismissed because significant liver disease can be found in PCR-negative donors, predominantly those who are RIBA positive. Follow-up and retesting of all the PCR-negative donors (55%-65%) will be more tedious and expensive than the first algorithm. Clearly, the choice between the two diagnostic algorithms depends on the availability of reliable PCR assays that can serve as the gold standard for the diagnosis of HCV infection. Early studies on stored sera reported that patients with chronic hepatitis C may be intermittently PCR negative. 38, 39 However, more recent studies found that the vast majority of patients with chronic hepatitis C who are not receiving interferon therapy are persistently viremic. 40, 41 Further studies using standardized PCR assays are needed to clarify the frequency of inter- Other individuals who are found to be anti-HCV (EIA-2)-positive with normal ALT levels should be evaluated using persistent hepatitis, but none had chronic active hepatitis or the same algorithm for blood donors. Although it is possible cirrhosis.
32,36,37 However, one study found that 17 of 34 that these individuals may have a false-positive EIA test result (50%) RIBA-positive, PCR-negative donors had chronic hep-or resolved HCV infection, many (especially those who are atitis, 4 of whom had chronic active hepatitis. 30 The high RIBA positive) are viremic, and some may develop elevated rate of significant liver disease in PCR-negative donors in the ALT levels on follow-up evaluation. Studies in EIA-2-posilatter study may be related to insensitivity of the PCR assay tive blood donors found that 40% to 60% had normal ALT because HCV RNA was detected in only 65% (64 of 98) of levels at the time of blood donation, but 30% to 50% of these RIBA-positive donors in contrast to the 89% detection rate donors developed intermittent or persistent elevation in ALT in other studies. 27, 31 These data suggest that RIBA-indetermi-levels during a 6-to 12-month follow-up period. 35, 42 Among nate donors who are PCR negative can be dismissed if the the RIBA-positive blood donors, HCV RNA was detected in PCR assay is reliable. One might even argue that HCV RNA 55% to 65% 30, 32 and chronic hepatitis in 30% to 70% 30, 35, [42] [43] [44] testing is unnecessary in donors who have isolated reactivity of those with persistently normal ALT levels. to C100 or 5-1-1. In view of the finding of chronic hepatitis Immunocompromised Patients. Immunocompromised patients such as hemodialysis patients and transplant recipients have in 21% to 50% of RIBA-positive, PCR-negative donors, reimpaired antibody response to HCV antigens, especially Ctesting for HCV RNA is recommended for these individuals 100 and 5-1-1. 45, 46 False-negative results in EIA-2 for antito exclude the possibility of intermittent viremia or false-HCV have been reported in 2.5% to 10.5% of patients who negative result because of suboptimal assay.
were PCR positive. 46-49 Thus, tests for HCV RNA should be The second algorithm is to test all EIA-2-positive blood performed in immunocompromised patients who are antidonors for HCV RNA by PCR assay because 60% to 70% will eventually be tested for HCV RNA. This is potentially a one-HCV negative when there is clinical suspicion of HCV infec- tion. In view of the complexity and high costs of PCR assays, hepatocellular carcinoma than in patients with chronic hepatitis. 24, 25, 72, [74] [75] [76] [77] [78] In addition, several studies found a higher it is impractical to recommend HCV RNA testing as the initial diagnostic test for these patients. Recent studies suggest that prevalence of genotype 1b among patients with chronic liver disease versus asymptomatic blood donors and individuals EIA-3 is more sensitive and can detect anti-HCV seroconversion earlier than EIA-2 in hemodialysis patients.
50,51 These with normal ALT levels. 25, 26, 79 Nevertheless, some of these studies also noted that patients with genotype 1b were data need to be confirmed.
Patients With Acute Hepatitis. Anti-HCV, as detected by EIA-older. 24, 25, 72, 79, 80 Thus, it is possible that longer duration of infection rather than genotype 1b per se accounted for the 2, is positive in approximately 50% of patients with acute hepatitis C at the time of presentation, and in 90% of patients more advanced liver disease. Other studies have not confirmed an association between genotype 1b and the presence at some point during the acute illness. 52 Tests for HCV RNA, preferably by qualitative PCR assays, permit earlier diagnosis of severe or advanced liver disease. 67, [81] [82] [83] Several reasons may account for the conflicting data: imbalance in the number and institution of treatment since several randomized controlled trials have shown that interferon therapy can reduce of patients with each genotype (many studies had very few patients with non-1b genotypes), failure to include patients the rate of chronic infection. [53] [54] [55] [56] [57] with the full spectrum of liver disease from asymptomatic
ASSESSMENT OF THE SEVERITY OF LIVER DISEASE
blood donors with normal ALT levels to hepatocellular carcinoma (some studies included patients with mild to severe Most patients with acute or chronic hepatitis C have no or nonspecific symptoms. Thus, history and physical exami-chronic hepatitis only), and different typing techniques (with the potential for misclassification). All the studies cited above nation are unreliable in assessing the severity of liver disease, except in patients with decompensated cirrhosis.
were cross-sectional studies. Two recent studies examined the relation between HCV Liver Biopsy. Liver histology is the gold standard for assessing the severity of liver disease. Liver biopsy is the only genotype and development of progressive liver disease with opposite conclusions. In one study, 136 Japanese patients means to diagnose well-compensated cirrhosis. It is useful in determining not only inflammatory activity but also the (96 type 1b, 36 type 2) were followed-up for a mean of 9.6 years (range, 5-26 years). The initial inflammatory and extent of fibrosis. Histological grading of inflammatory activity and staging of fibrosis have also been shown to correlate fibrosis scores were comparable between patients with types 1 and 2. However, patients with genotype 1 had significantly with the risk of subsequent progression to cirrhosis. 58 In addition, fibrosis score or cirrhosis has been identified to be higher inflammatory as well as fibrosis scores on the followup biopsies compared with patients with genotype 2. 84 In one of the most important independent predictive factors for response to interferon treatment. [59] [60] [61] [62] [63] addition, a significantly higher percentage of patients with genotype 1 developed hepatocellular carcinoma during folSerum Aminotransferase Levels. Although anti-HCV-positive patients who have elevated ALT levels are more likely low-up (29% vs. 5.6%; P õ .001). These findings differed from those in a second study in which 85 Italian patients to have significant liver disease on liver biopsy than those who have persistently normal ALT levels, 25 histological evi-(47 type 1, 30 type 2) were followed-up for a mean of 66.9 months (range, 12-119 months). 21 There was no correlation dence of chronic hepatitis can be found in 30% to 70% of RIBA-2-and PCR-positive individuals despite persistently between HCV genotypes and progression of liver disease, death, or development of hepatocellular carcinoma. Studies normal ALT levels. Among patients with elevated ALT levels, there is a weak correlation between the ALT level and histo-in liver transplant recipients with recurrent hepatitis C also reached opposite conclusions. Two studies reported more logical diagnosis or histology activity index. 64 Serum HCV RNA Level. Regardless of the assay used to severe liver disease in patients with genotype 1b, 85,86 but these findings were not confirmed in another study. 87 quantify serum HCV RNA levels, all published studies found no correlation between serum HCV RNA and ALT levIt is unclear if genotype 1b is more pathogenic. Because a wide spectrum of liver disease has been found in association els.
8,41,43,65-68 Several studies have reported that blood donors with normal ALT levels tended to have lower serum HCV with each genotype, genotyping does not help in assessing the severity of liver disease, and until further data become RNA levels than patients with chronic hepatitis C. [69] [70] [71] However, other investigators failed to confirm these observa-available, genotyping has no role in predicting prognosis. tions. 43 Data on the correlation between serum HCV RNA
EVALUATION FOR TREATMENT
level and liver histology are conflicting. Some studies found no correlation, 67,72 one study reported lower serum HCV Once the diagnosis of HCV infection is confirmed and the severity of liver disease has been assessed, patients should RNA levels in patients with more advanced liver disease, 12 whereas other studies demonstrated progressive increase in be evaluated for treatment. The decision to treat or not to treat depends on many factors, including age of the patient, serum HCV RNA levels in patients with more advanced liver disease. 20, 65, 73 In view of the overlap in serum HCV RNA presence of symptoms, severity of liver disease, likelihood of response to treatment, concomitant medical problems, and levels among patients with different stages of liver disease, quantifying HCV RNA levels in serum will not help in as-contraindications to the use of interferon therapy. In general, the decision should be made jointly by the physician and sessing the severity of liver disease.
HCV Genotyping. Many investigators have examined the re-patient after the latter has been informed of the pros and cons of treatment. lation between HCV genotype and severity of liver disease.
Most of the studies have focused on comparisons between
The most important factors that have been identified to be associated with a favorable response to interferon treatgenotype 1b and other genotypes, predominantly types 2 and 3. The vast majority of these studies reported a higher ment are low pretreatment serum HCV RNA level, HCV genotype non-1, and low fibrosis score or lack of cirrhosis. prevalence of genotype 1b among patients with cirrhosis and AID Hepa 0007 / 5p25$$$122 08-01-97 08:22:12 hepas WBS: Hepatology The goals of treatment are sustained biochemical (normalization in ALT level) and virological (undetectable HCV RNA NOTE. Odds ratio, 4.37 (95% confidence interval, 3.12-6.14).
in serum) response. It is now recognized that in some patients there is a discrepancy between biochemical and virological response 100 and that patients who normalize their ALT Serum HCV RNA Level. Every study that has examined the relation between pretreatment serum HCV RNA level and level but remain HCV RNA positive are more likely to relapse than those who have normal ALT and undetectable HCV response to interferon therapy has concluded that low pretreatment serum HCV RNA level is associated with a higher RNA levels. 60, 101 Because the aim is to determine viral clearance, the most sensitive test (qualitative PCR assay) should rate of response.
11-14,59,61,88-96 The difference is more striking when sustained response was compared against transient and be used. bDNA assay has no role in defining virological response. The most appropriate time for testing is just before no response. Response in most of these studies was defined as normalization in serum ALT level. In several studies, low completion of treatment. However, there is no data to suggest that prolonging treatment in patients who have achieved biopretreatment serum HCV RNA level was found to be associated with favorable response regardless of the genotype. 88, 90, 92 chemical but not virological response after 6 to 12 months of therapy will achieve viral clearance if treatment is prolonged. These findings suggest that all patients considered for treatment should have quantification of serum HCV RNA level.
Several studies have shown that early normalization of ALT level (week 12) is associated with biochemical response The results can be used to counsel patients on the likelihood of response and may influence the patient's decision on treat-at the end of treatment. 102 Continuing treatment at the same or higher doses in patients who failed to normalize their ALT ment. However, there is insufficient data at this stage to define inclusion or exclusion criteria for treatment based on levels after 12 weeks of interferon treatment at 3-millionunit doses is associated with very low rate of sustained reserum HCV RNA level. It is also unclear which assay should be used for quantification. The bDNA assay is technically sponse. 103, 104 These data suggest that treatment should be withdrawn in patients who failed to normalize their ALT easy, highly reproducible, has good linearity and similar efficiencies for various genotypes, but it is less sensitive; there-levels after 12 weeks of treatment. However, one study reported histological improvement in patients who completed fore, patients who have undetectable HCV RNA in the bDNA assay would need to be tested by the PCR assay to ascertain a long course (18 months) of interferon therapy despite their failure to normalize ALT levels. 105 This observation needs to that they are viremic before treatment. Quantitative PCR assays are more sensitive but tedious to perform, poorly stan-be confirmed before changing our current recommendation to withdraw treatment based on lack of initial ALT response. dardized, inconsistent, have variable efficiencies for different genotypes, and have limited range of linearity. 97 Recent studies reported an association between rapid viral clearance and sustained response to interferon therapy. 106, 107 Many published studies used in-house quantitative PCR assays that are poorly standardized, and the results were In one study, clearance of HCV RNA at week 4 was the best predictor of sustained biochemical response; HCV RNA expressed in different units. Studies that used bDNA assays for quantification of pretreatment serum HCV RNA level became undetectable by week 4 in 73%, 26%, and 0% of the found that the odds ratio for sustained biochemical response in patients who were PCR positive but bDNA negative was 4.4 (95% confidence interval, 3.1-6.1) compared with those patients who had, respectively, sustained, transient, and no liver disease in individuals who are RIBA positive but PCR negative, the predictive value of pretreatment serum HCV response (P Å .02). 106 These data suggest that the decision to discontinue treatment based on failure of initial response RNA level for sustained (biochemical and virological) response to interferon treatment, and the criteria for withmay be made earlier by testing for viral clearance. However, these data were based on small numbers of patients. Further drawal of treatment based on lack of initial response. studies using more standardized PCR assays are needed to REFERENCES define the optimal time for assessment of initial response that will identify all sustained responders without including by PCR assay 6 to 12 months after completion of therapy 64:191-192. to document sustained virological response. More frequent (Table 3 ). In general, qualitative PCR assay for serum HCV levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in RNA is the best confirmatory test. However, EIA-positive assay (Table 3) . Liver biopsy is the most reliable means to Clearly, the most important task at hand is to standardize 
